BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017. The NextGen Bio Class of 2019 is a stellar group of companies that are already making an enormous impact on the industry now and will continue into the future. Congratulations to this group! Skyhawk Therapeutics Points : 17 Launched : 2018 Location : Waltham, MA Notable: • In June 2018, Skyhawk Therapeutics closed a $40 million equity investment round and then, in an unusual deal, signed a five-year collaborative agreement with Celgene that included an upfront $60 million. • Skyhawk focuses on developing small molecule therapeutics that correct RNA mis-splicing, what is usually called exon skipping. • The company expects to move its first oncology treatment into the clinic in 2019. • Skyhawk currently has four targets in oncology and three in neuro, which are in lead selection but past preclinical IND filing.
For more information visit: www.skyhawktx.com https://www.linkedin.com/company/skyhawk-therapeutics/ https://twitter.com/Skyhawk_Tx
SKYHAWK MEDIA CONTACT: Maura McCarthy maura@skyhawktx.com